|
IL-15 Enhanced NK Cell Therapy for Solid Tumors
RECRUITINGEarly 1Sponsored by Genovn Therapeutics (Suzhou) Co., Ltd.
Actively Recruiting
PhaseEarly 1
SponsorGenovn Therapeutics (Suzhou) Co., Ltd.
Started2026-10-08
Est. completion2028-12-31
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07621471
Summary
A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.
Eligibility
Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Age 18-70 years; 2. ECOG 0-1; 3. histopathologically confirmed metastatic or recurrent solid tumors (breast, liver, lung, etc.); 4. failed prior standard therapy; 5. \>=1 measurable lesion per RECIST 1.1; 6. adequate bone marrow, liver, kidney, and coagulation function; 7. recovered from prior treatment toxicities; 8. signed informed consent. Exclusion Criteria: 1. Pregnancy/lactation; 2. other malignancy within 5 years (except cured localized tumors); 3. active autoimmune disease or immunodeficiency; 4. uncontrolled cardiovascular disease or infection; 5. active TB; 6. positive HBsAg/HBcAb or HCV antibody (unless viral load undetectable); 7. positive syphilis antibody; 8. major surgery or vaccination within 28 days; 9. prior cell therapy; 10. severe allergy to study drugs; 11. investigator judged unsuitable.
Conditions3
CancerMetastatic CancerSolid Tumors
Interventions1
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseEarly 1
SponsorGenovn Therapeutics (Suzhou) Co., Ltd.
Started2026-10-08
Est. completion2028-12-31
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07621471